Status:
COMPLETED
Incretin Effect in People With Impaired Fasting Glucose
Lead Sponsor:
University of Colorado, Denver
Conditions:
Obesity
Eligibility:
All Genders
45-70 years
Phase:
NA
Brief Summary
Regulation of endogenous glucose production (EGP) and insulin secretion are major actions of glucagon-like peptide-1 (GLP-1). Determining whether alterations in GLP-1 may contribute to abnormal EGP an...
Eligibility Criteria
Inclusion
- Healthy, sedentary, non-smokers, men and women 45-70 years old Subjects were placed into 1 of the 2 groups based on two 2-hour 75g oral glucose tolerance tests (2h OGTT), separated by one week: a control group with normal glucose tolerance (NGT; n=14; fasting glucose \<5.6 mmol/l and 2h OGTT \<7.8 mmol/l), or IFG (n=10; fasting glucose 5.6-6.9 mmol/l, and 2h OGTT \<7.8 mmol/l).
Exclusion
- Subjects were excluded for: thyroid stimulating hormone \<50 or \>500 milliunits/L, fasting triglycerides \>10.3 mmol/l, creatinine \>130 μmol/l, elevated liver function tests (\>2 times normal), hematocrit \< 38%, or white blood cell count \<3.0 x 103. Use of medications for lipid and/or glucose lowering also excluded enrollees. Women may not have used hormone replacement therapy in the past 1 year. Smokers. BMI \<25 or \>40 kg/m2. Diabetes or impaired glucose tolerance.
Key Trial Info
Start Date :
January 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2008
Estimated Enrollment :
26 Patients enrolled
Trial Details
Trial ID
NCT00795275
Start Date
January 1 2008
End Date
November 1 2008
Last Update
April 5 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Colorado Denver
Aurora, Colorado, United States, 80045